Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980018/S026

HercepTest

Agilent Technologies Singapore (International) Pte , Ltd. · Decision date Jan 28, 2026

FDA DECISIONP980018/S026

What did the FDA approve?

FDA records P980018/S026 as a supplement to PMA P980018, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jan 28, 2026.

FDA approval order statement

Approval for specific labeling change to provide clearer instructions for use, which will improve user compliance and reduce errors, thereby ensuring consistent staining results.
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Pathology
Decision date
Jan 28, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P980018/S026
Regulatory pathway
PMA supplement
Product code
MVC
Decision code
APPR
Decision date
Jan 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: SYSTEM, TEST, HER-2/NEU, IHC.

Product code
MVC
FDA device class
3

For the original device and its historical approval scope, see PMA P980018. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P980018/S026 received

    Application receipt date recorded by FDA.

  2. P980018/S026 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P980018. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980018

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies Singapore (International) Pte , Ltd.PMA approvalSep 25, 1998FDA
HercepTestP980018/S027
Agilent Technologies Singapore (International) Pte , Ltd.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Other records with product code MVC

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies Singapore (International) Pte , Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
# 1 Yishun Ave. 7, Singapore, 768923

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records